COVID-19 ventilated in the same unit and patients who had viral pneumonitis arising from viruses other than SARS-CoV-2. Why this increased susceptibility should be present remains uncertain, as the noted reports adjusted for duration of ventilation, it is likely that the increased susceptibility relates impaired innate immunity in the lungs. However several observational studies have identified the use of glucocorticoids as a factor associated with increased risk of VAP and other Hospital-acquired infections. References Further reading External links Pneumonia Respiratory therapy